Transitioning from preclinical to clinical development is a critical step in drug development, often accompanied by significant challenges. This webinar will explore key considerations from a clinical pharmacology perspective, and explore potential solutions to establish a robust plan for your First-In-Human study.
Speaker: Tom Habraken
Tom is the Group Leader of Clinical Consultancy at Venn Life Sciences. With a MSc in Drug Innovation from Utrecht University, Tom joined Venn in 2019 as Clinical Pharmacokinetics (PK) Consultant and has been involved in clinical development since 2015.
- 9 years of experience in the pharma industry
- Expert in PK and PD consultancy in clinical studies & early clinical drug development & studies
- Experienced in multiple therapeutic areas with a main focus on oncology
- Organiser of the Pharmacokinetics Course at Venn, providing a clear overview of the role of PK and PD in drug development
Key Learnings:
- The Key Elements in the Transition From Preclinical to Clinical
- How the Target Population Shapes First-In-Human Trials for Your Drug
- Understanding the Role of Drug-Drug Interactions in the Early Clinical Development of Your Drug
- Handling Unexpected Pharmacokinetic Results in Your First-In-Human Study
